Evaluating biomarkers for predicting subarachnoid haemorrhage
Evaluation of the Predictive Value of Serum Glial Fibrillary Acidic Protein and Ubiquitin Carboxy-terminal Hydrolase L1 for Subarachnoid Haemorrhage
This study is testing two blood markers to see if they can help doctors quickly and accurately diagnose subarachnoid hemorrhage in patients who have had a lumbar puncture.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 900 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Royal Wolverhampton Hospitals NHS Trust Government |
| Locations | 1 site (Wolverhampton, West Midlands) |
| Trial ID | NCT06581757 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the diagnostic accuracy of two biomarkers, GFAP and UCH-L1, in predicting subarachnoid haemorrhage (SAH). The study will analyze serum samples collected from patients who have undergone a lumbar puncture (LP) within 24 hours. By verifying the performance of these biomarkers, the research seeks to improve early diagnosis and treatment of SAH, which is critical for patient outcomes. The study highlights the limitations of current diagnostic methods and aims to reduce unnecessary procedures.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 18 and older who have undergone a lumbar puncture with a serum sample taken within 24 hours.
Not a fit: Patients who do not meet the age requirement or have not had a lumbar puncture within the specified timeframe may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely diagnoses of subarachnoid haemorrhage, potentially improving patient outcomes.
How similar studies have performed: While the use of biomarkers in diagnosing SAH is a growing field, this specific evaluation of GFAP and UCH-L1 is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥18 years old, who have had an LP with a serum sample taken within 24 hours of the LP. Exclusion Criteria: -
Where this trial is running
Wolverhampton, West Midlands
- New Cross Hospital — Wolverhampton, West Midlands, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Leanne Young — The Royal Wolverhampton NHS Trust
- Study coordinator: Leanne Young
- Email: leanne.young6@nhs.net
- Phone: +44 7789480536
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.